DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

2026-08-10 · TIRZEPATIDE · TopGLP1Providers Data Desk

The first year on tirzepatide, priced month by month

A first year of compounded tirzepatide costs from $1,380 (NexLife’s 12-month plan, read November 20, 2026) to $7,164 (the highest August capture, billed monthly), with the FDA-approved benchmark at roughly $5,388 for a maintenance-dose year of Zepbound vials. Which of those numbers becomes yours is decided in the first ninety days, by three structural choices this roadmap walks through in order.

Released · Last reviewed · how we verify

Months one and two: the on-ramp, and the first structural fork. Standard titration starts at 2.5 mg, which is where advertised prices live. On a dose-flat program you pay the real price from day one — $129 at NexLife↗ (read November 20, 2026), $258 at Yucca (August capture) — and nothing changes later. On a tiered program you pay the teaser now and find out later: an advertised $133 with no published maintenance figure is a month-one price wearing a year-one costume. On the brand path, LillyDirect↗ charges $299 for the 2.5 mg vial — genuinely the cheapest brand month you will ever have. The month-two decision that matters most is not financial at all: it is whether you tolerate the medication, because everything prepaid should wait until that answer exists.

Months three through five: titration, where tiered pricing shows its hand. The ladder typically moves through 5 and 7.5 mg here. Flat programs: no invoice change. Brand: the 5 mg vial steps to $399, then the 7.5 mg to $449, and Lilly’s 45-day refill clock starts mattering — miss a window and the maintenance rate reverts toward list. Tiered compounded programs reprice each step, which is why this is the quarter to demand the written 10 mg and 15 mg figures if you did not get them at signup. This is also the earliest point at which a prepaid term becomes a reasonable bet: by month three you know your tolerance, your dose trajectory, and whether the program’s operations match its marketing. NexLife’s 3-month plan at $125/month ($375, read November 20, 2026) is the shape of that first sensible commitment.

Months six through nine: maintenance, where the real price lives. Most people stabilize around 10 mg — the basis every ranking on this site uses, because it is the number the rest of the year is billed at. On flat programs your month-six invoice equals your month-one invoice. On tiered programs this is where the advertised-versus-billed gap peaks; on brand, disciplined refills hold $449. This is also the window to re-shop once, deliberately: with tolerance and dose known, the calculator answers in one pass whether a switch or a longer prepaid term ($119/month at six months, $115 at twelve, at NexLife) beats your incumbent.

Months ten through twelve: the anniversary math. Totals at current figures: a monthly-billed year at NexLife runs $1,548 and its 12-month plan $1,380 (November 20, 2026); the mid-market cluster (IVIM Health↗, Mochi Health↗) lands near $3,336; brand at maintenance about $5,388. The spread between the cheapest and most expensive realistic paths for the same molecule over the same year exceeds $5,700 — which is the entire argument for treating the first year as a sequence of priced decisions rather than one signup. The annual-cost analysis holds the full program-by-program table; this roadmap is the order in which to use it.

Dose timelines above describe standard titration as public fact, not a plan for you; dosing decisions belong to your prescriber.

The cheapest compounded tirzepatide online rigThe cheapest compounded semaglutide online, inCompounded tirzepatide vs ZepboundWhat a year of tirzepatide actually costs, proDose-flat vs dose-tiered pricing

Primary sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.